KR102634320B1 - Composition for diagnosing bee venom allergy comprising phospholipase A2 as an active ingredient - Google Patents
Composition for diagnosing bee venom allergy comprising phospholipase A2 as an active ingredient Download PDFInfo
- Publication number
- KR102634320B1 KR102634320B1 KR1020220170830A KR20220170830A KR102634320B1 KR 102634320 B1 KR102634320 B1 KR 102634320B1 KR 1020220170830 A KR1020220170830 A KR 1020220170830A KR 20220170830 A KR20220170830 A KR 20220170830A KR 102634320 B1 KR102634320 B1 KR 102634320B1
- Authority
- KR
- South Korea
- Prior art keywords
- bee venom
- phospholipase
- composition
- allergy
- diagnosing
- Prior art date
Links
- 239000003659 bee venom Substances 0.000 title claims abstract description 65
- 208000034280 venom allergy Diseases 0.000 title claims abstract description 40
- 102100037611 Lysophospholipase Human genes 0.000 title claims abstract description 21
- 108010058864 Phospholipases A2 Proteins 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000004480 active ingredient Substances 0.000 title claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 11
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 13
- 230000007815 allergy Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 101710099833 Venom protein Proteins 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000004885 tandem mass spectrometry Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 101000924591 Apis mellifera Apamin Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- YVIIHEKJCKCXOB-STYWVVQQSA-N molport-023-276-178 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)CC(C)C)[C@@H](C)O)C(N)=O)C1=CNC=N1 YVIIHEKJCKCXOB-STYWVVQQSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
본 발명은 포스포리파아제 A2(Phospholipase A2)를 유효성분으로 포함하는 봉독 알레르기 진단용 조성물에 관한 것으로, 봉독(bee venom)에서 유래한 포스포리파아제 A2가 봉독에 특이적으로 반응하는 면역글로불린 E(immunoglobulin E)와 항원-항체 반응을 나타내는 것을 확인함으로써, 봉독 알레르기 진단용 조성물로서 유용하게 활용될 수 있다.The present invention relates to a composition for diagnosing bee venom allergy containing phospholipase A2 as an active ingredient. Phospholipase A2 derived from bee venom is an immunoglobulin E that specifically reacts to bee venom. E), it can be usefully used as a composition for diagnosing bee venom allergy by confirming that it exhibits an antigen-antibody reaction.
Description
본 발명은 포스포리파아제 A2(Phospholipase A2)를 유효성분으로 포함하는 봉독 알레르기 진단용 조성물에 관한 것이다.The present invention relates to a composition for diagnosing bee venom allergy containing phospholipase A2 as an active ingredient.
알레르기(Allergy)는 면역시스템의 오작동으로, 보통 사람에게는 별 영향이 없는 물질이 특정 사람에게만 두드러기, 가려움, 콧물, 기침 등의 과민반응을 유발하는 질환으로서, 환경오염, 식생활과 생활습관의 서구화, 스트레스 등과 같은 환경인자, 유전 및 다양한 알레르겐에 의해 유발될 수 있다. 전 세계적으로 알레르기 환자 수가 꾸준히 증가하고 있어, 알레르기 진단, 치료, 예방 등을 위한 연구가 활발히 진행되고 있다.Allergy is a malfunction of the immune system. It is a disease in which substances that have no effect on ordinary people cause hypersensitivity reactions such as hives, itching, runny nose, and cough in only certain people. It is caused by environmental pollution, westernization of diet and lifestyle, It can be caused by environmental factors such as stress, genetics, and various allergens. As the number of allergy patients is steadily increasing worldwide, research on allergy diagnosis, treatment, and prevention is actively underway.
알레르기 반응은 그 반응 형태에 의해 I형, II형, III형 및 IV형의 4가지 유형으로 분류될 수 있다. 또한, 상기 4가지 유형은 다시 항원에 의한 재감작(感作) 후 발증까지의 시간에 의해서 I형, II형 및 III형 알레르기는 즉시형 알레르기, IV형 알레르기는 지연형 알레르기로 분류될 수 있다. I형 알레르기는 면역글로불린 E(Immunoglobulin E; IgE) 항체가 관여하는 반응으로서, 아나필락시스형 알레르기라고 불리며, 기관지 천식, 아토피성 질환(피부염, 장염 등), 화분증 등의 알레르기성 비염, 알레르기성 결막염, 음식물 알레르기 등이 포함된다.Allergic reactions can be classified into four types according to the type of reaction: type I, type II, type III, and type IV. In addition, the above four types can be classified into immediate-type allergies for type I, type II, and type III allergies, and delayed-type allergies for type IV allergies, depending on the time until onset after re-sensitization by an antigen. . Type I allergy is a reaction involving immunoglobulin E (IgE) antibodies and is called anaphylactic allergy, including bronchial asthma, atopic diseases (dermatitis, enteritis, etc.), allergic rhinitis such as hay fever, allergic conjunctivitis, This includes food allergies, etc.
봉독(Bee venom)은 꿀벌의 복부 끝 독낭에 저장된 산성 및 염기성 분비물의 혼합물로서, 자극 시에 산란관에서 나오는 독액을 말하며, 동물성 천연 생리활성 물질이다. 봉독을 구성하는 성분으로는 폴리펩타이드(Polypeptides), 효소(Enzymes), 아민류(Amines), 분자량이 작은 비펩타이드 성분의 화합물(Nonpeptide components) 등 약 40가지의 성분이 있다. 특히, 멜리틴(melittin, 40-50%), 포스포리파제 A2(phospholipase A2, 10-12%) 및 아파민(apamine, 2-3%)이 봉독의 주요 성분이다. 이들 성분은 각각 혹은 상호작용을 통해 농도 및 용량에 따라 항염, 진통, 항암 작용 등을 나타낸다고 알려져 있다. 특히 항염 작용의 경우, NF-κB 활성 억제를 통해 염증성 사이토카인을 감소시키고, 산소기 생성을 억제하며, 전신적으로 부신수질 호르몬을 자극하는 등 다양한 기전으로 항염 작용을 나타낸다고 알려져 있다. 이에, 봉독은 항염, 진통, 항암 등의 용도로서 의약품, 건강기능식품 등으로 사용되고 있으나, 봉독에 대해서도 알레르기 반응이 나타나는 경우가 있어, 봉독 알레르기가 있는지 확인한 후, 복용해야 할 필요가 있다.Bee venom is a mixture of acidic and basic secretions stored in the venom sac at the end of the bee's abdomen. It refers to the venom released from the ovipositor when stimulated, and is a natural physiologically active substance of animal origin. There are about 40 components that make up bee venom, including polypeptides, enzymes, amines, and nonpeptide components with low molecular weight. In particular, melittin (40-50%), phospholipase A2 (10-12%), and apamine (2-3%) are the main components of bee venom. These ingredients are known to exhibit anti-inflammatory, analgesic, and anticancer effects depending on concentration and dose, individually or through interaction. In particular, in the case of anti-inflammatory action, it is known to exhibit anti-inflammatory action through various mechanisms, such as reducing inflammatory cytokines through inhibition of NF-κB activity, suppressing oxygen radical production, and stimulating systemic adrenal medullary hormones. Accordingly, bee venom is used as medicine, health functional food, etc. for anti-inflammatory, pain-relieving, anti-cancer purposes, etc. However, there are cases where allergic reactions to bee venom occur, so it is necessary to check whether there is an allergy to bee venom before taking it.
본 발명의 목적은 서열번호 1로 표시되는 아미노산 서열로 이루어진 포스포리파아제 A2(Phospholipase A2) 항원을 유효성분으로 포함하는 봉독 알레르기 진단용 조성물을 제공하는 것이다.The purpose of the present invention is to provide a composition for diagnosing bee venom allergy containing the phospholipase A2 antigen consisting of the amino acid sequence shown in SEQ ID NO: 1 as an active ingredient.
본 발명의 다른 목적은 상기 봉독 알레르기 진단용 조성물을 포함하는 봉독 알레르기 진단용 키트를 제공한다.Another object of the present invention is to provide a kit for diagnosing bee venom allergy, including the composition for diagnosing bee venom allergy.
본 발명의 또 다른 목적은 상기 봉독 알레르기 진단용 조성물을 개체에서 분리된 생물학적 시료와 반응시켜, 포스포리파아제 A2(Phospholipase A2) 항원과 특이적으로 반응하는 면역글로불린 E(immunoglobulin E)의 항원-항체 반응을 통해 봉독 알레르기 유무를 분석하는 단계를 포함하는, 봉독 알레르기 진단에 필요한 정보 제공 방법을 제공하는 것이다.Another object of the present invention is to react the composition for diagnosing bee venom allergy with a biological sample isolated from an individual to produce an antigen-antibody reaction of immunoglobulin E that specifically reacts with the phospholipase A2 antigen. The aim is to provide a method of providing information necessary for diagnosing bee venom allergy, including the step of analyzing the presence or absence of bee venom allergy.
상기 목적을 달성하기 위해, 본 발명은 서열번호 1로 표시되는 아미노산 서열로 이루어진 포스포리파아제 A2(Phospholipase A2) 항원을 유효성분으로 포함하는 봉독 알레르기 진단용 조성물을 제공한다.To achieve the above object, the present invention provides a composition for diagnosing bee venom allergy containing the phospholipase A2 antigen consisting of the amino acid sequence shown in SEQ ID NO: 1 as an active ingredient.
또한, 본 발명은 상기 봉독 알레르기 진단용 조성물을 포함하는 봉독 알레르기 진단용 키트를 제공한다.Additionally, the present invention provides a kit for diagnosing bee venom allergy, including the composition for diagnosing bee venom allergy.
또한, 본 발명은 상기 봉독 알레르기 진단용 조성물을 개체에서 분리된 생물학적 시료와 반응시켜, 포스포리파아제 A2(Phospholipase A2) 항원과 특이적으로 반응하는 면역글로불린 E(immunoglobulin E)의 항원-항체 반응을 통해 봉독 알레르기 유무를 분석하는 단계를 포함하는, 봉독 알레르기 진단에 필요한 정보 제공 방법을 제공한다.In addition, the present invention reacts the composition for diagnosing bee venom allergy with a biological sample isolated from an individual, through antigen-antibody reaction of immunoglobulin E, which specifically reacts with the phospholipase A2 antigen. Provides a method of providing information necessary for diagnosing bee venom allergy, including the step of analyzing the presence or absence of bee venom allergy.
본 발명에 따르면, 봉독(bee venom)에서 유래한 포스포리파아제 A2(Phospholipase A2)가 봉독에 특이적으로 반응하는 면역글로불린 E(immunoglobulin E)와 항원-항체 반응을 나타내는 것을 확인함으로써, 봉독 알레르기 진단용 조성물로서 유용하게 활용될 수 있다.According to the present invention, by confirming that phospholipase A2 derived from bee venom exhibits an antigen-antibody reaction with immunoglobulin E, which specifically reacts to bee venom, it can be used to diagnose bee venom allergy. It can be usefully used as a composition.
도 1은 봉독 알레르기 진단용 신속 항원 키트의 모식도이다.
도 2는 봉독 단백질을 SDS-PAGE를 수행하여, 크기에 따라 단백질을 분리하고, 쿠마시브릴리언트 블루 염색 용액(Coomassie Brilliant Blue staining solution)을 이용하여 단백질이 검출되었음을 확인한 결과이다.
도 3은 봉독 단백질을 분자생물학적인 방법으로 재조합 DNA를 이용하여 재조합 단백질을 생산 및 정제하는 과정을 나타내는 모식도이다.Figure 1 is a schematic diagram of a rapid antigen kit for diagnosing bee venom allergy.
Figure 2 shows the results of performing SDS-PAGE on bee venom proteins, separating the proteins according to size, and confirming that the proteins were detected using Coomassie Brilliant Blue staining solution.
Figure 3 is a schematic diagram showing the process of producing and purifying a recombinant protein using recombinant DNA using a molecular biological method.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 서열번호 1로 표시되는 아미노산 서열로 이루어진 포스포리파아제 A2(Phospholipase A2) 항원을 유효성분으로 포함하는 봉독 알레르기 진단용 조성물을 제공한다.The present invention provides a composition for diagnosing bee venom allergy containing as an active ingredient the phospholipase A2 antigen consisting of the amino acid sequence shown in SEQ ID NO: 1.
상기 포스포리파아제 A2는 봉독(bee venom)에서 유래한 것일 수 있다.The phospholipase A2 may be derived from bee venom.
본 발명에서, “진단”은 병리 상태의 존재 또는 특징을 확인하는 것을 의미한다. 본 발명에 있어서, 진단은 봉독 알레르기의 위험이 있는지 또는 봉독 알레르기의 발병 여부를 확인하거나, 나아가 봉독 알레르기의 진행 여부 또는 심화 여부를 확인하는 것을 의미할 수 있다.In the present invention, “diagnosis” means confirming the presence or characteristics of a pathological condition. In the present invention, diagnosis may mean confirming whether there is a risk of bee venom allergy or whether bee venom allergy has developed, or further, confirming whether bee venom allergy has progressed or worsened.
또한, 본 발명은 상기 봉독 알레르기 진단용 조성물을 포함하는 봉독 알레르기 진단용 키트를 제공한다.Additionally, the present invention provides a kit for diagnosing bee venom allergy, including the composition for diagnosing bee venom allergy.
상기 키트는 봉독 알레르기가 의심되는 개체로부터 분리된 생물학적 시료에서 봉독과 특이적으로 반응하는 면역글로불린 E(immunoglobulin E)의 항원-항체 반응을 통해 봉독 알레르기 발병 여부를 진단하는 데 사용될 수 있다.The kit can be used to diagnose bee venom allergy through the antigen-antibody reaction of immunoglobulin E, which specifically reacts with bee venom, in biological samples isolated from individuals suspected of having bee venom allergy.
또한, 상기 키트는 도 1과 같은 형태일 수 있고, 상기 포스포리파아제 A2 항원 외에 봉독 알레르기 진단에 적합한 조성물, 용액 또는 장치를 추가로 포함할 수 있다.Additionally, the kit may have the form shown in Figure 1, and may further include a composition, solution, or device suitable for diagnosing bee venom allergy in addition to the phospholipase A2 antigen.
또한, 본 발명은 상기 봉독 알레르기 진단용 조성물을 개체에서 분리된 생물학적 시료와 반응시켜, 포스포리파아제 A2(Phospholipase A2) 항원과 특이적으로 반응하는 면역글로불린 E(immunoglobulin E)의 항원-항체 반응을 통해 봉독 알레르기 유무를 분석하는 단계를 포함하는, 봉독 알레르기 진단에 필요한 정보 제공 방법을 제공한다.In addition, the present invention reacts the composition for diagnosing bee venom allergy with a biological sample isolated from an individual, through antigen-antibody reaction of immunoglobulin E, which specifically reacts with the phospholipase A2 antigen. Provides a method of providing information necessary for diagnosing bee venom allergy, including the step of analyzing the presence or absence of bee venom allergy.
상기 생물학적 시료는 조직, 세포, 전혈, 혈액, 혈청, 타액, 객담, 뇌척수액 및 뇨로 이루어진 군에서 선택된 하나 이상일 수 있으나, 이에 한정되는 것은 아니다.The biological sample may be one or more selected from the group consisting of tissue, cells, whole blood, blood, serum, saliva, sputum, cerebrospinal fluid, and urine, but is not limited thereto.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, the present invention will be described in detail through examples to aid understanding. However, the following examples only illustrate the content of the present invention and the scope of the present invention is not limited to the following examples. Examples of the present invention are provided to more completely explain the present invention to those skilled in the art.
[[ 실험예Experiment example 1] One] 봉독bee venom 단백질 제조 protein manufacturing
봉독 단백질을 제조하기 위해, 봉독 단백질은 청진바이오텍에서 구매한 정제 봉독을 PBS(Phosphate buffered saline)에 녹여 100mg/mL 농도로 사용하였다. 제조한 단백질은 SDS-PAGE를 통해 크기에 따라 단백질을 분리하고, 도 2에 나타난 바와 같이, 쿠마시브릴리언트 블루 염색 용액(Coomassie Brilliant Blue staining solution)을 이용하여 단백질이 검출되었음을 확인하였다.To prepare bee venom protein, purified bee venom purchased from Cheongjin Biotech was dissolved in PBS (Phosphate buffered saline) and used at a concentration of 100 mg/mL. The prepared protein was separated according to size through SDS-PAGE, and as shown in Figure 2, it was confirmed that the protein was detected using Coomassie Brilliant Blue staining solution.
[[ 실시예Example 1] One] 봉독bee venom 알레르기 진단 물질 분석 Allergy diagnostic material analysis
상기 실험예 1에서 제조한 봉독 단백질 내에서 봉독 알레르기 진단 물질을 확인하기 위해, 봉독 알레르기 환자군 및 정상군의 혈청을 무작위로 선별하고, 사람 면역글로불린 E(Immunoglobulin E; 이하 IgE라 함)와 항원-항체 반응을 나타내는 물질을 분석하였다. In order to identify bee venom allergy diagnostic substances in the bee venom protein prepared in Experimental Example 1, sera from bee venom allergy patients and normal groups were randomly selected, and human immunoglobulin E (Immunoglobulin E; hereinafter referred to as IgE) and antigen- Materials showing antibody reactions were analyzed.
봉독 단백질로 SDS-PAGE 진행한 겔(gel)의 목적하는 단백질 밴드를 절제하고, 트립신(trypsin)과 함께 in-gel digestion하였다. 절제된 겔을 50%(v/v) 아세토나이트릴(acetonitrile)이 함유된 pH 7.8의 25mM 탄산수소암모늄(ammonium bicarbonate) 버퍼를 이용해서 상온에서 1시간 동안 세척하고, 원심 진공 농축기(centrifugal vacuum concentrator)를 이용해 탈수시킨 후, 50ng sequencing grade 트립신 용액에 재수화하였다. 그 후, 37℃ 및 pH 7.8의 25mM 탄산수소암모늄 버퍼에 하루 동안 배양(incubation)하고, 트립신 펩타이드를 20분 동안 50%(v/v) 아세토나이트릴을 포함하는 100μL의 1% 포름산(formic acid)에 처리한 후, 초음파로 추출하였다. 추출된 용액은 원심 진공 농축기를 이용해 농축하고, 질량분석에 앞서, 펩타이드 용액은 역상 컬럼(reversed-phase column)을 이용해 탈염(desalting) 과정을 거치게 하였다. The target protein band was excised from the gel subjected to SDS-PAGE with bee venom protein and subjected to in-gel digestion with trypsin. The excised gel was washed for 1 hour at room temperature using 25mM ammonium bicarbonate buffer, pH 7.8, containing 50% (v/v) acetonitrile, and centrifugal vacuum concentrator. After dehydration using , it was rehydrated in 50ng sequencing grade trypsin solution. Afterwards, the tryptic peptides were incubated in 25mM ammonium bicarbonate buffer at 37°C and pH 7.8 for one day, and the tryptic peptides were incubated in 100 μL of 1% formic acid containing 50% (v/v) acetonitrile for 20 minutes. ) and then extracted with ultrasound. The extracted solution was concentrated using a centrifugal vacuum concentrator, and prior to mass spectrometry, the peptide solution was subjected to a desalting process using a reversed-phase column.
LC-MS/MS 분석은 nano ACQUITY UPLC 및 LTQ-orbitrap-mass spectrometer(Thermo Electron, San Jose, CA)를 통해 수행하였고, 컬럼은 BEH C18 1.7μm, 100μm × 100mm 컬럼(Waters, Milford, MA, USA)을 사용하였다. LC에서 이동상 A는 0.1% 포름산이 포함된 증류수를 사용하였고, 이동상 B는 0.1% 포름산이 포함된 아세토나이트릴을 사용하였다. 크로마토그래피 gradient는 유량 0.5μL/min으로 설정하였고, 10% B에서 40% B로 16분 동안, 40% B에서 95% B로 8분 동안, 90% B에서 10% B로 11분 동안 선형적으로 증가하도록 설정하였다. LC-MS/MS analysis was performed using a nano ACQUITY UPLC and LTQ-orbitrap-mass spectrometer (Thermo Electron, San Jose, CA), and the column was a BEH C18 1.7 μm, 100 μm × 100 mm column (Waters, Milford, MA, USA). ) was used. In LC, mobile phase A used distilled water containing 0.1% formic acid, and mobile phase B used acetonitrile containing 0.1% formic acid. The chromatographic gradient was set at a flow rate of 0.5 μL/min and was linear from 10% B to 40% B over 16 min, from 40% B to 95% B over 8 min, and from 90% B to 10% B over 11 min. It was set to increase.
tandem 질량 분석에서 질량 스펙트럼은 전체 질량 스캔(300~2000m/z)과 MS/MS 스캔을 사용한 데이터 의존적 수집을 통해 수집하였다. 이온 전달 튜브의 온도는 275℃, 스프레이는 2.3kV로 설정하였고, 정규화된 충돌 에너지는 MS/MS의 경우 35%로 설정하였다. 또한, MS/MS의 개별 스펙트럼은 SEQEST 소프트웨어(Thermo Quest, San Jose, CA, USA)를 사용하여 처리하였고, 생성된 피크 목록은 마스코트 프로그램(Matrix Science Ltd, 영국 런던)을 사용하였다. MS 분석을 위한 Carbamidomethyl(C), Deamidated(NQ), Oxidation(M)의 변형을 설정하였고, 펩타이드 질량의 허용오차는 10ppm, MS/MS 이온 질량 공차는 0.8Da, 빗나간 균열의 허용치는 2로 설정하였다. In tandem mass spectrometry, mass spectra were collected through data-dependent acquisition using full mass scans (300–2000 m/z) and MS/MS scans. The temperature of the ion transfer tube was set at 275°C, the spray was set at 2.3kV, and the normalized collision energy was set at 35% for MS/MS. Additionally, individual spectra of MS/MS were processed using SEQEST software (Thermo Quest, San Jose, CA, USA), and the generated peak list was generated using the Mascot program (Matrix Science Ltd, London, UK). For MS analysis, the modifications of Carbamidomethyl (C), Deamidated (NQ), and Oxidation (M) were set, the tolerance for peptide mass was set to 10 ppm, the MS/MS ion mass tolerance was set to 0.8 Da, and the tolerance for stray cracks was set to 2. did.
상기 내용에 따라, 봉독 단백질을 추출하여 SDS-PAGE 겔로 분리한 후, PVDF 멤브레인(membrane)에 transfer하였다. 그 후, 봉독 알레르기 환자의 혈액을 감작시켜 혈액과 반응하는 밴드를 확인하고, 상기 밴드를 추출하여 Mass Spectrometer로 분석을 하여 동정하였다. 그 결과, 표 1에 나타난 바와 같이, 봉독의 항원(allergen)으로 동정된 단백질은 봉독 내 포스포리파아제 A2(Phospholipase A2)인 것을 확인하였다. 상기 결과로부터, 봉독에서 유래한 포스포리파아제 A2를 IgE와 항원-항체 반응을 통해 봉독 알레르기 진단에 활용 수 있음을 확인하였다.According to the above, bee venom proteins were extracted, separated on an SDS-PAGE gel, and then transferred to a PVDF membrane. Afterwards, the blood of a patient allergic to bee venom was sensitized to identify a band that reacted with the blood, and the band was extracted and identified by analysis with a mass spectrometer. As a result, as shown in Table 1, it was confirmed that the protein identified as the allergen of bee venom was phospholipase A2 in bee venom. From the above results, it was confirmed that phospholipase A2 derived from bee venom can be used to diagnose bee venom allergy through IgE and antigen-antibody reaction.
daccrthdmc pdvmsagesk hgltntasht rlscdcddkf ydclknsadt issyfvgkmy
fnlidtkcyk lehpvtgcge rtegrclhyt vdkskpkvyq wfdlrkymqvvlgslfl lllstshgwq irdrigdnel eeriiypgtl wcghgnkssg pnelgrfkht
daccrthdmc pdvmsagesk hgltntasht rlscdcddkf ydclknsadt issyfvgkmy
fnlidtkcyk lehpvtgcge rtegrclhyt vdkskpkvyq wfdlrky
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 즉, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다.As the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present invention. do. That is, the practical scope of the present invention is defined by the appended claims and their equivalents.
Claims (5)
상기 조성물은 개체에서 분리된 생물학적 시료와 반응시켜, 포스포리파아제 A2(Phospholipase A2) 항원과 특이적으로 반응하는 면역글로불린 E(immunoglobulin E)의 항원-항체 반응을 통해 봉독 알레르기 유무를 분석하는 것을 특징으로 하고,
상기 생물학적 시료는 전혈, 혈액 및 혈청으로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 하는 봉독 알레르기 진단용 조성물.A composition for diagnosing bee venom allergy containing as an active ingredient a phospholipase A2 antigen consisting of the amino acid sequence shown in SEQ ID NO: 1,
The composition is reacted with a biological sample isolated from an individual to analyze the presence or absence of bee venom allergy through an antigen-antibody reaction of immunoglobulin E, which specifically reacts with the phospholipase A2 antigen. And,
A composition for diagnosing bee venom allergy, wherein the biological sample is at least one selected from the group consisting of whole blood, blood, and serum.
상기 키트는 개체에서 분리된 생물학적 시료와 반응시켜, 포스포리파아제 A2(Phospholipase A2) 항원과 특이적으로 반응하는 면역글로불린 E(immunoglobulin E)의 항원-항체 반응을 통해 봉독 알레르기 유무를 분석하는 것을 특징으로 하고,
상기 생물학적 시료는 전혈, 혈액 및 혈청으로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 하는 봉독 알레르기 진단용 키트.A kit for diagnosing bee venom allergy comprising the composition of claim 1 or claim 2,
The kit reacts with a biological sample isolated from an individual and analyzes the presence or absence of bee venom allergy through an antigen-antibody reaction of immunoglobulin E, which specifically reacts with the phospholipase A2 antigen. And,
A kit for diagnosing bee venom allergy, wherein the biological sample is at least one selected from the group consisting of whole blood, blood, and serum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220170830A KR102634320B1 (en) | 2022-12-08 | 2022-12-08 | Composition for diagnosing bee venom allergy comprising phospholipase A2 as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220170830A KR102634320B1 (en) | 2022-12-08 | 2022-12-08 | Composition for diagnosing bee venom allergy comprising phospholipase A2 as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102634320B1 true KR102634320B1 (en) | 2024-02-08 |
Family
ID=89899824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220170830A KR102634320B1 (en) | 2022-12-08 | 2022-12-08 | Composition for diagnosing bee venom allergy comprising phospholipase A2 as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102634320B1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100297188A1 (en) * | 2007-12-21 | 2010-11-25 | Giovanni Mistrello | Allergens and allergoids from bee venom |
| KR101469167B1 (en) * | 2012-02-27 | 2014-12-04 | 경희대학교 산학협력단 | Composition for preventing or treating diseases related to abnormal suppression of regulatory T cell activation comprising bee venom-derived PLA2 |
| KR20180009443A (en) * | 2016-07-18 | 2018-01-29 | (주)프로테옴텍 | Biochip for diagnosing medicinal herbs allergy |
| EP1846556B1 (en) * | 2004-12-14 | 2018-04-11 | PLS-Design GmbH | Cloning of honey bee allergen |
| KR20180056478A (en) | 2016-11-18 | 2018-05-29 | (의료)길의료재단 | A microarray kit for diagnosing antigens causing allergic rhinitis and preparation method thereof |
-
2022
- 2022-12-08 KR KR1020220170830A patent/KR102634320B1/en active IP Right Grant
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1846556B1 (en) * | 2004-12-14 | 2018-04-11 | PLS-Design GmbH | Cloning of honey bee allergen |
| US20100297188A1 (en) * | 2007-12-21 | 2010-11-25 | Giovanni Mistrello | Allergens and allergoids from bee venom |
| KR101469167B1 (en) * | 2012-02-27 | 2014-12-04 | 경희대학교 산학협력단 | Composition for preventing or treating diseases related to abnormal suppression of regulatory T cell activation comprising bee venom-derived PLA2 |
| US20150150951A1 (en) * | 2012-02-27 | 2015-06-04 | Hyun Su Bae | Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity |
| KR20180009443A (en) * | 2016-07-18 | 2018-01-29 | (주)프로테옴텍 | Biochip for diagnosing medicinal herbs allergy |
| KR20180056478A (en) | 2016-11-18 | 2018-05-29 | (의료)길의료재단 | A microarray kit for diagnosing antigens causing allergic rhinitis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| Muller U et al, Clinical & Experimental Allergy (1997.), vol 27, no 8, pp 915-920. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Misra et al. | Potential allergens of green gram (Vigna radiata L. Millsp) identified as members of cupin superfamily and seed albumin | |
| Burkova et al. | Exosomes from human placenta purified by affinity chromatography on sepharose bearing immobilized antibodies against CD81 tetraspanin contain many peptides and small proteins | |
| US20210353598A1 (en) | Antigen-driven detection and treatment of coccidioidomycosis | |
| Pshezhetsky et al. | Subcellular proteomics of cell differentiation: Quantitative analysis of the plasma membrane proteome of Caco‐2 cells | |
| Yin et al. | A combined proteomic and metabolomic strategy for allergens characterization in natural and fermented Brassica napus bee pollen | |
| Mani et al. | Identification of Ligustrum lucidum pollen allergens using a proteomics approach | |
| He et al. | Identification of potential allergens in larva, pupa, moth, silk, slough and feces of domestic silkworm (Bombyx mori) | |
| KR102634320B1 (en) | Composition for diagnosing bee venom allergy comprising phospholipase A2 as an active ingredient | |
| KR102634321B1 (en) | Composition for diagnosing deer antler allergy comprising albumin as an active ingredient | |
| CN111537716A (en) | Haemonchus contortus early infection diagnostic kit | |
| CN111423495B (en) | Rapana venosa polypeptide with oxidative stress damage resistance and preparation method and application thereof | |
| JP4343702B2 (en) | Method for producing hypoallergenic birch pollen major allergen rBetv1 | |
| WO2008112424A1 (en) | Assessing heart failure | |
| KR102190300B1 (en) | Compositions for diagnosis of allergy disease to silkworm, methods for diagnosing of allergy disease to silkworm, and composition for immunotherapy of allergy disease to silkworm | |
| US20090068687A1 (en) | Screening platform for discovery of immunomodulatory activities in traditional medicine | |
| JP3983260B2 (en) | Atopic dermatitis attractant | |
| KR101997142B1 (en) | A biomarker for diagnosing asthma comprising nectin-4 and the uses thereof | |
| KR20210033775A (en) | Compositions for diagnosis of allergy to Fagales plant pollen, diagnosis methods using the same, and composition for prevention or treatment of allergy to Fagales plant pollen | |
| Areshidze et al. | Anti-inflammatory effect of Nicavet-2500 in rodent models of acute inflammation | |
| RU2819906C2 (en) | Veterinary product | |
| Rodriques | Molecular and Proteomic Characterization of Bla g 2 Allergen in the German Cockroach (Blattella germanica L.) | |
| Li et al. | Preparation and detection of sea snake antisera raised in rabbits | |
| KR102107056B1 (en) | Compositions for diagnosis of allergy disease to mite, methods for diagnosing of allergy disease to mite, and composition for prevention or treatment of allergy disease to mite | |
| KR102288646B1 (en) | Glycan Biomarker for Diagnosing Osteoarthritis of Pets and Method for Diagnosing Osteoarthritis of Pets Using the Same | |
| Gonzáles de Olano et al. | Identification of a novel 17-kDa protein as a ferret allergen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A302 | Request for accelerated examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |